Abstract
Filoviruses (ebolaviruses and marburgviruses) cause severe hemorrhagic fever in humans and nonhuman primates with high mortality rates of up to 90 %. The latest epidemic of Ebola virus disease in Western African countries has underscored the urgent need for effective prophylactic and therapeutic interventions for this deadly infectious disease. However, neither approved prophylactics nor therapeutics are currently available for filovirus diseases. Recent studies have been unveiling the molecular mechanisms underlying the filovirus lifecycle, including cellular entry, egress, and the evasion from host immunity, suggesting possibilities to develop effective pan-filovirus drugs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.